The PP2Aalpha+beta antibody is designed to detect both the alpha (PR65α) and beta (PR65β) isoforms of the structural A subunit of Protein Phosphatase 2A (PP2A), a critical serine/threonine phosphatase involved in diverse cellular processes. PP2A exists as a heterotrimeric holoenzyme composed of a scaffolding A subunit, a catalytic C subunit, and a regulatory B subunit. The A subunit serves as a structural platform, with two major isoforms (alpha and beta) encoded by separate genes (PPP2R1A and PPP2R1B). While these isoforms share ~85% sequence homology, they exhibit distinct expression patterns: PP2Aα is ubiquitously expressed, whereas PP2Aβ shows tissue-specific localization, particularly in the brain and heart.
Antibodies targeting both isoforms enable researchers to study PP2A’s roles in cell cycle regulation, signal transduction, apoptosis, and metabolism without distinguishing between the two A subunit variants. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to assess PP2A expression, localization, and protein interactions. Dysregulation of PP2A, including altered A subunit expression, has been implicated in cancer, neurodegenerative diseases (e.g., Alzheimer’s), and cardiovascular disorders. By detecting total A subunit levels, the PP2Aalpha+beta antibody aids in exploring disease mechanisms or therapeutic responses linked to PP2A dysfunction. Its broad applicability makes it a valuable tool for investigating PP2A’s complex biology across physiological and pathological contexts.